Literature DB >> 27384385

Stage-directed individualized therapy in esophageal cancer.

Lucas Goense1,2, Peter S N van Rossum1,2, Daniela Kandioler3, Jelle P Ruurda1, Khean-Lee Goh4, Misha D Luyer5, Mark J Krasna6, Richard van Hillegersberg7.   

Abstract

Esophageal cancer is the eighth most common cancer worldwide, and the incidence of esophageal carcinoma is rapidly increasing. With the advent of new staging and treatment techniques, esophageal cancer can now be managed through various strategies. A good understanding of the advances and limitations of new staging techniques and how these can guide in individualizing treatment is important to improve outcomes for esophageal cancer patients. This paper outlines the recent progress in staging and treatment of esophageal cancer, with particularly attention to endoscopic techniques for early-stage esophageal cancer, multimodality treatment for locally advanced esophageal cancer, assessment of response to neoadjuvant treatment, and the role of cervical lymph node dissection. Furthermore, advances in robot-assisted surgical techniques and postoperative recovery protocols that may further improve outcomes after esophagectomy are discussed.
© 2016 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals Inc. on behalf of The New York Academy of Sciences.

Entities:  

Keywords:  anastomotic leakage; esophageal cancer; esophageal surgery; neoadjuvant chemoradiation; robot-assisted; tumor staging

Mesh:

Substances:

Year:  2016        PMID: 27384385     DOI: 10.1111/nyas.13113

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.

Authors:  Bin Wei; Jiru Wang; Xiaohui Zhang; Zhaoye Qian; Jingjing Wu; Yuan Sun; Qin Han; Li Wan; Jing Zhu; Yong Gao; Xiaofei Chen
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

2.  Integrin α5 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells.

Authors:  Sicong Hou; Weiguo Jin; Weiming Xiao; Bin Deng; Dacheng Wu; Jiehua Zhi; Keyan Wu; Xiaowei Cao; Shuai Chen; Yanbing Ding; Hongcan Shi
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

3.  MIR548P and TRAV39 Are Potential Indicators of Tumor Microenvironment and Novel Prognostic Biomarkers of Esophageal Squamous Cell Carcinoma.

Authors:  Jian Xu; Long Tang; Zhiqiang Wang; Qi Zhang; Yuequan Jiang
Journal:  J Oncol       Date:  2022-09-17       Impact factor: 4.501

4.  Inhibition of survivin enhances radiosensitivity of esophageal cancer cells by switching radiation-induced senescence to apoptosis.

Authors:  Xianghe Liu; Yahui Zhao; Weina Zhang; Yang Gao; Miaomiao Huo; Mei Liu; Zefen Xiao; Shufang Liang; Ningzhi Xu; Hongxia Zhu
Journal:  Onco Targets Ther       Date:  2018-05-24       Impact factor: 4.147

5.  Predicting lymph node metastases with endoscopic resection in cT2N0M0 oesophageal cancer: A systematic review and meta-analysis.

Authors:  Ali Al-Kaabi; Rachel S van der Post; Jonathan Huising; Camiel Rosman; Iris D Nagtegaal; Peter D Siersema
Journal:  United European Gastroenterol J       Date:  2019-09-25       Impact factor: 4.623

6.  Stromal microenvironment promoted infiltration in esophageal adenocarcinoma and squamous cell carcinoma: a multi-cohort gene-based analysis.

Authors:  Jiali Li; Zihang Zeng; Xueping Jiang; Nannan Zhang; Yanping Gao; Yuan Luo; Wenjie Sun; Shuying Li; Jiangbo Ren; Yan Gong; Conghua Xie
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.